Compare · DXCM vs LUNG
DXCM vs LUNG
Side-by-side comparison of DexCom Inc. (DXCM) and Pulmonx Corporation (LUNG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and LUNG operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 469.8x LUNG ($62.9M).
- DXCM has been more active in the news (26 items in the past 4 weeks vs 6 for LUNG).
- DXCM has more recent analyst coverage (25 ratings vs 17 for LUNG).
- Company
- DexCom Inc.
- Pulmonx Corporation
- Price
- -
- -
- Market cap
- $29.57B
- $62.9M
- 1M return
- +25.71%
- -
- 1Y return
- -10.56%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2020
- News (4w)
- 26
- 6
- Recent ratings
- 25
- 17
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Pulmonx Corporation
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest LUNG
- Pulmonx Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Science &Techn. Officer Radhakrishnan Srikanth sold $22,325 worth of shares (14,497 units at $1.54), decreasing direct ownership by 4% to 331,239 units (SEC Form 4) to cover withholding tax
- GENERAL COUNSEL Lehman David Aaron sold $22,475 worth of shares (14,594 units at $1.54), decreasing direct ownership by 4% to 376,161 units (SEC Form 4) (withholding obligation)
- CHIEF COMMERCIAL OFFICER Rose Geoffrey Beran sold $12,355 worth of shares (8,023 units at $1.54), decreasing direct ownership by 2% to 457,711 units (SEC Form 4) (for withholding tax)
- President and CEO French Glendon E. Iii sold $86,875 worth of shares (56,149 units at $1.55), decreasing direct ownership by 5% to 1,178,162 units (SEC Form 4) (withholding tax)
- Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 10-Q filed by Pulmonx Corporation
- Pulmonx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Pulmonx Reports First Quarter 2026 Financial Results
- Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference